A 40th anniversary Corvette was sold at a Barrett-Jackson auction to benefit the TGen Cancer Research Fund, named after Jackson family members who died from colon cancer. The sale raised over $250,000 for the fund, with all proceeds going towards life-changing research.
Philanthropists Foster and Lynn Friess are tripling-match donations up to $100,000 for TGen's unTEAL a cure event. The total raised will support groundbreaking research on ovarian cancer cases.
Dr. Von Hoff's research and clinical work advance personalized cancer treatment by analyzing patients' DNA sequences to determine the best course of treatment. His work has improved patient outcomes and paved the way for individualized healthcare based on genetic factors.
A study by Mayo Clinic and TGen found that patients are willing to undergo many tests for advanced experimental treatment in clinical trials. Patients were most willing to undergo non-invasive tests such as urine, blood, and imaging studies, but less willing to undergo invasive procedures like skin biopsies and MRIs.
Researchers identified 27 genes that influence the effectiveness of oxaliplatin in treating colorectal cancer. The study highlights the need for further clinical research to improve treatment outcomes and reduce side effects associated with the drug.
A new study aims to discover the genetic and molecular underpinnings of small cell carcinoma of the ovary (SCCO), a rare and aggressive cancer affecting young women. Researchers will collect tumor and blood samples using advanced genomic approaches to understand the disease's origins and develop effective treatments.
The 2010 Golf Atlanta charity golf tournament raised $105,000 to support investigations into pancreatic cancer at The Translational Genomics Research Institute. The event drew 124 players and included a high-end auction with donations supporting TGen's life-changing research.
A study by Mayo Clinic and TGen reveals that DNA methylation is altered with increasing severity in multiple myeloma, leading to the overexpression of oncogenes. The researchers found hypomethylation at specific points of DNA, associated with myeloma development, and suggest it may have prognostic value.
Researchers have found a gene associated with aggressive skin cancer, INPP5A, which could predict its onset and track its progression. The study suggests that targeting this gene may provide new ways to prevent and treat cutaneous squamous cell carcinoma.
Researchers at TGen have identified two potential anti-cancer drug targets, STK10 and TNK2, for Ewing's sarcoma in children. These kinases play a crucial role in the growth and survival of cancer cells, making them promising therapeutic targets.
The Marilyn B. Gula Mountains of Hope Foundation has donated $50,000 to the Translational Genomics Research Institute (TGen) for advanced breast cancer research and treatment. The donation will support groundbreaking research into the genetic components of common and complex diseases, including advanced breast cancer.
The Genomic SQueeZ (G-SQZ) compression technique developed by TGen can compress genomic sequencing data by up to 80 percent, reducing storage needs and costs. This technology allows for selective content access and maintaining the relative order of the data.
Researchers at TGen have found a way to revive chemotherapy in ovarian cancer patients who no longer respond to conventional treatment. By inhibiting the CHEK1 protein, they were able to make these cells sensitive again to cisplatin, a widely used platinum-based chemotherapy drug.
The Arizona Myeloma Network recognized Dr. Jeffrey Trent, President of the Translational Genomics Research Institute (TGen), for his organization's support of cancer patients and events such as the 'All Cancers' run. This recognition acknowledges TGen's involvement in patient-advocacy organizations like AzMN.
Researchers at TGen discovered a genetic biomarker with significant association to kidney failure in American Indians in Arizona. The study found evidence of some lesser associations between kidney failure and four other markers, all linked to the SUCNR1 gene.
Researchers at TGen and VARI discovered a biomarker, miR-92a-2*, linked to survival in SCLC patients. Higher tumor levels of this microRNA are associated with chemoresistance and decreased survival.
A man and his two Great Pyrenees embark on a 2,000-mile walk to raise awareness about cancer in dogs while collecting DNA samples for a new $5.3 million canine cancer project. The TGen-VARI program aims to discover the causes of cancer in dogs and potentially translate findings to humans.
The Lung Cancer Research Foundation donated $25,000 to support TGen's lung cancer research, recognizing the institute's groundbreaking work in improving detection and treatment. This marks the second year of the 'Strides for Life' event, which aims to advance lung cancer research.
Dr. James Bogenberger has been awarded a 3-year fellowship to research acute myeloid leukemia at TGen, with the goal of identifying therapeutic targets that sensitize AML to epigenetic therapies. The fellowship project aims to translate state-of-the-art biomedical research into novel targeted therapy approaches for leukemia patients.
The Anne Rita Monahan Foundation has raised $50,000 for ovarian cancer research at the Translational Genomics Research Institute (TGen). Funds from the 2nd annual Tea for TEAL event will support the development of a reliable screening test and precision therapy for ovarian cancer.
A TGen and VARI program is studying naturally occurring cancers in dogs to better understand the causes of disease and develop new treatments. The goal is to translate knowledge into therapeutics that can help both humans and animals, with a focus on rare sarcomas and osteosarcoma.
Dr. Von Hoff, TGen's Physician-in-Chief, has been recognized with the David A. Karnofsky Memorial Award and Lecture at ASCO's Annual Meeting. He is a renowned physician-scientist who has contributed to developing numerous anticancer agents.
A new clinical trial at the Virginia G. Piper Cancer Center uses molecular profiling to identify specific treatments for refractory breast cancer. The trial aims to keep cancer under control for longer periods and potentially shrink tumors.
Businessman-philanthropist Foster Friess will match donations up to $50,000 to support TGen's ovarian cancer research. The event has already raised nearly $38,000, with over 500 participants expected.
TGen Drug Development and Rondaxe Enterprises announce a strategic alliance to help emerging companies bring high-quality treatments to market. The partnership focuses on maximizing value proposition through drug development and manufacturing strategies, bridging the gap between chemistry and translational medicine.
TGen Breast and Ovarian Cancer Research Unit making significant progress in three key areas of breast cancer research: genetic events, cellular mechanics, and genomic tests. The donations raised by Safeway will help find new treatments for breast cancer patients.
A TGen-led team has identified three kinases that cause hyperphosphorylation of tau protein, leading to the dismantling of microtubule bridges within brain cells. This process disrupts synaptic connections and can lead to memory loss and thinking problems associated with Alzheimer's disease.
Researchers at TGen Clinical Research Services have discovered three microRNAs that can predict patients with small-cell lung cancer who will be resistant to first-line chemotherapy. These biomarkers, miR-92a-2*, miR-147, and miR-574-5p, were identified through a study of 34 patients with varying stages of SCLC.
A study published by The Translational Genomics Research Institute found that circumcision significantly alters the bacterial communities of the penis, reducing anaerobic bacteria and increasing aerobic bacteria. This change may contribute to lower HIV risk and protection against bacterial vaginosis in women.
Researchers at TGen identified genetic markers associated with end-stage renal disease in diabetics, providing hope for early diagnosis and prevention. The study found eight locations along the human genome tied to ESRD, including six potential markers for Type 1 diabetes.
A TGen team won a $1,000 prize for their research on identifying microRNAs and imaging features associated with lung cancer metastasis to the brain. The study used microRNAs and imaging characteristics from CT and PET scans as biomarkers to predict brain metastases.
A new swine flu test developed by TGen can quickly inform doctors about the strain of flu and whether it may be resistant to oseltamivir, a primary anti-viral drug. The test has been shown to be effective in detecting resistance to Tamiflu in H1N1 virus strains.
Casework Genetics has developed a new technology to overcome mixed sample complexity, enabling law enforcement labs to solve crimes with greater precision and efficiency. The technology uses ultra high-density Single Nucleotide Polymorphisms (SNPs) arrays to distinguish characters within DNA.
The Translational Genomics Research Institute has been awarded $691,930 to develop brain tumor research using in silico simulations. The project will utilize comprehensive genomic data involving 40 brain tumor models and 20 proven types of targeted therapies.
Researchers identified metabolic pathways in lung cancer cells that can be targeted by drugs, providing potential new treatment options. The study used computer simulations to validate these findings and highlights the value of in silico research in speeding up the development of new cancer treatments.
The University of Arizona College of Pharmacy and the Translational Genomics Research Institute have been awarded a $7.5 million grant to establish a comprehensive center for drug discovery and development. The center aims to assemble a team capable of designing and selecting drug candidates to respond quickly to unmet medical needs.
A clinical trial at Scottsdale Healthcare-TGen demonstrated tumor shrinkage and limited side effects in patients with advanced basal cell carcinoma. The therapy, which targets the Hedgehog signaling pathway, offers new hope for this aggressive form of skin cancer.
Researchers from TGen and Scottsdale Healthcare presented two significant advances in treating lung cancer, including a potential method to prevent brain metastasis. A drug called TH-302 showed promising results in clinical trials, achieving stable disease or better in 75% of patients with small cell lung cancer.
A TGen-led research team has been awarded a $1 million grant by the Melanoma Research Alliance to identify novel melanoma risk genes. The team, led by Dr. Jeffrey Trent, aims to characterize genes influencing melanoma risk and develop targeted screening or prevention efforts.
Researchers at UC Berkeley and TGen found a gene variant, rs6457327, associated with nearly twice the risk of developing follicular lymphoma, a cancer of the body's disease-fighting network. The presence of the G allele was protective against the disease, while the A allele increased risk.
A TGen-led team has identified five genetic biomarkers that may predict response to the anti-diabetes drug Actos, enabling personalized medicine for patients with type 2 diabetes. These markers were found in genes associated with PPARG function and include variants in a key drug metabolizing gene called cytochrome P450 3A4.
A $18 million grant will support a three-year investigation into new approaches to treating pancreatic cancer, the fourth leading cause of cancer death in the US. The project aims to develop tests that determine what nutrients fuel pancreatic cancer cell growth and survival.
A nationwide study by TGen and Scottsdale Healthcare shows that molecular profiling can identify specific treatments for individuals, helping keep their cancer in check for significantly longer periods. The study included 66 patients who experienced significant periods of time when their tumors did not progress.
TGen researchers have identified a potential therapeutic target for glioblastoma multiforme (GBM) by regulating the actions of NHERF-1, a gene implicated in tumor cell migration and division. Depletion of NHERF-1 stops GBM cell migration, suggesting its role in tumor invasion.
The grocery chain has increased its contribution to TGen by 37% over 2008, with the donation representing a significant boost to breast cancer research. The funds will be used to develop treatments and eventually find a cure for breast cancer.
A drug used to treat stroke patients may also improve learning and memory and reduce the risk of Alzheimer's disease, according to a new study. The active form of the parent drug Fasudil improved spatial learning and working memory in middle-aged rats.
In a groundbreaking study, researchers have identified a common variant in the GRM7 gene as being associated with susceptibility to glutamate excitotoxicity and hearing loss. The findings could lead to treatments that bring relief to millions of people worldwide suffering from age-related hearing loss.
A TGen-led team found a link between the brain protein KIBRA and reduced Alzheimer's disease risk in individuals with the T-allele gene. The study suggests that KIBRA may play a role in Alzheimer's disease, providing promising new targets for treatments.
Researchers at TGen have devised a faster and less expensive way to identify genetic variants in the human genome. By using bar-coded multiplexed sequencing, scientists can index portions of the nearly 3-billion-base genetic code, making it easier to zero in on regions most likely to show variations in genetic traits.
Researchers at TGen and Washington University School of Medicine have discovered a new approach to treating endometrial cancer using a commercially available inhibitor drug. The study found that the drug can stop tumor growth and kill cancer cells, even in cases where the tumors contain a commonly occurring mutant gene.